拓扑替康为主联合方案治疗难治急性髓系白血病的临床观察

Clinical study of the effect of topotecan-based induced therapy on refractory acute myeloid leukemia

目的探讨以拓扑替康为主的治疗方案对难治急性髓系白血病的疗效及不良反应。方法采用以拓扑替康为基础的联合诱导方案治疗难治急性髓系白血病10例(原发难治急性髓系白血病6例,慢性粒细胞白血病急变4例)。其中5例治疗1个疗程,其余5例治疗2个疗程。结果2例达完全缓解,5例达部分缓解,总缓解率为70%,3例无反应。不良反应主要表现为白细胞及血小板减少的骨髓抑制。结论以拓扑替康为基础的诱导缓解方案对部分难治急性髓系白血病患者具有确切疗效。

Objective To observe the effects and side-effects of cyclophosphamide, cytarabine, topotecan （CAT） combination regimen for treatment of refractory acute myeloid leukemia （AML）. Methods Ten patients with refractory AML were treated with CAT chemotherapy, 5 accepted 1 course, and the others accepted 2 courses. Results Two patients achieved complete remission, 5 had partial remission. The total response rate was 70 %. Three had no response. The main adverse effects were myelosuppression characterized by remarkably decreased numbers of white blood cell and platelet. Conclusion The topotecan-based induction therapy has anti-leukemic effect in some patients with refractory AML.